Evidence map›Paper›PMID 21239695›Full record

Trial reportBlood2011

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

Jonathan W Friedberg, Julie M Vose, Jennifer L Kelly, Faith Young, Steven H Bernstein, Derick Peterson, Lynn Rich, Susan Blumel, Nicole K Proia, Jane Liesveld and 4 more

Registry-linked trialOpen access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00547534 (Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma), which is not on this map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00547534 phase2completednot on this map

Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma

TypeinterventionalSponsorUniversity of RochesterRan2007 to 2009Enrolled31ConditionsNon-Hodgkin's LymphomaArmsbortezomib, bendamustine, rituximab
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 192 citations in OpenAlex.

  1. Pooled it
  2. Non-Hodgkin's lymphomas, version 4.2014.Journal of the National Comprehensive Cancer Network : JNCCN · 2014
    Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Sequencing of Novel Therapies for Mantle Cell Lymphoma.Current treatment options in oncology · 2021
    Review
  17. Review
  18. Review
  19. Review
  20. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.International journal of molecular sciences · 2019
    Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Jonathan W FriedbergJames P. Wilmot Cancer Center, University of Rochester, Rochester, NYm, USA. jonathan_friedberg@urmc.rochester.edu
Julie M Vose
Jennifer L Kelly
Faith Young
Steven H Bernstein
Derick Peterson
Lynn Rich
Susan Blumel
Nicole K Proia
Jane Liesveld
Richard I Fisher
James O Armitage
Steven Grant
John P Leonard
University of Rochester · USUniversity of Nebraska Medical Center · USCornell University · USVirginia Commonwealth University · US

Funding

Checkpoint Abrogation and MEK 1/2 Inhibition in MyelomaR01CA100866 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2003 to 2013
$2.2M
NCI NIH HHS R01 CA100866
6 · The paper itself

Abstract

Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequate organ function were treated with bendamustine 90 mg/m² days 1 and 4; rituximab 375 mg/m² day 1, and bortezomib 1.3 mg/m² days 1, 4, 8, 11. Six 28-day cycles were planned. Thirty patients (7 with mantle cell lymphoma) were enrolled and treated. Eight patients experienced serious adverse events, including one event of grade 5 sepsis. Common nonhematologic adverse events were generally grade 1 or grade 2 and included nausea (50%), neuropathy (47%), fatigue (47%), constipation (40%), and fever (40%). Of 29 patients evaluable for efficacy, 24 (83%) achieved an objective response (including 15 with complete response). With median follow-up of 24 months, 2-year progression-free survival is 47% (95% confidence interval, 25%-69%). On the basis of these promising results, the US cooperative groups have initiated randomized trials to evaluate this regimen in follicular and mantle cell lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00547534.

Indexed as

Antibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBoronic AcidsBortezomibFemaleHumansKaplan-Meier EstimateLymphoma, Mantle-CellMaleMiddle AgedNeoplasm Recurrence, LocalNitrogen Mustard CompoundsPyrazinesRituximabAntibodies, Monoclonal, Murine-DerivedBendamustine HydrochlorideBoronic AcidsBortezomibNitrogen Mustard CompoundsPyrazinesRituximab

Identifiers

PMID21239695
PMCPMC3062293
OpenAlexW1985343909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.